Fingolimod 0.5 mg reduced annualized relapse rate by 73.4 % ( P = 0.0002 ) versus IFN-1a IM and by 67.4 % ( P < 0.0001 ) versus placebo in patients with < 3 years since first symptom ; respective reductions were 45.4 % and 51.4 % in subgroups of patients with 3 years since first symptom .